Page last updated: 2024-11-05

troglitazone and Diabetic Angiopathies

troglitazone has been researched along with Diabetic Angiopathies in 13 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.

Research Excerpts

ExcerptRelevanceReference
" Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure."4.79[Treatment of hypertension associated with diabetes mellitus]. ( Katayama, S, 1997)
"Troglitazone treatment resulted in an average 75% increase in the adiponectin levels, but no changes were observed in the endothelium-dependent vasodilation, any other measurement of vascular reactivity, or any other markers of endothelial activation."2.71Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes. ( Buras, J; Horton, ES; Orlow, D; Reenstra, WR; Veves, A, 2005)
"Troglitazone therapy was associated with increases in LDL size (26."2.70Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. ( Armstrong, D; Baxi, S; Caulfield, M; Chu, NV; Deutsch, R; Henry, RR; Kim, DD; Kong, AP; Mudaliar, SR; Reaven, PD; Reitz, R, 2002)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (23.08)18.2507
2000's10 (76.92)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Raji, A1
Plutzky, J1
Caballero, AE1
Saouaf, R1
Lim, SC1
Hamdy, O1
Abou-Elenin, K1
O'Connor, C1
Logerfo, FW1
Horton, ES2
Veves, A2
Muniyappa, R1
El-Atat, F1
Aneja, A1
McFarlane, SI1
Verrier, E1
Wang, L1
Wadham, C1
Albanese, N1
Hahn, C1
Gamble, JR1
Chatterjee, VK1
Vadas, MA1
Xia, P1
Jawa, AA1
Fonseca, VA1
Buras, J1
Reenstra, WR1
Orlow, D1
Katayama, S1
Murakami, T1
Mizuno, S1
Ohsato, K1
Moriuchi, I1
Arai, Y1
Nio, Y1
Kaku, B1
Takahashi, Y1
Ohnaka, M1
Zimmet, P1
Collier, G1
Takagi, T1
Akasaka, T1
Yamamuro, A1
Honda, Y1
Hozumi, T1
Morioka, S1
Yoshida, K1
Marcus, AO1
Chu, NV1
Kong, AP1
Kim, DD1
Armstrong, D1
Baxi, S1
Deutsch, R1
Caulfield, M1
Mudaliar, SR1
Reitz, R1
Henry, RR1
Reaven, PD1
Makino, N1
Hirayama, H1
Yonemochi, H1
Yano, K1
Abe, N1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)[NCT00819910]Phase 441 participants (Actual)Interventional2008-09-30Terminated (stopped due to Slow recruitment and increase in deployment overseas limiting follow up)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percent Change in Triglyceride (TG) Levels Post Treatment

The reported percent change is the difference between TG levels obtained on initial visit (day 0) and TG levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)

Intervention% change (Mean)
Rosiglitazone + Placebo7.4
Fenofibrate + Placebo-2.2
Rosiglitazone +Fenofibrate20
Placebo Therapy Daily7.6

Post-treatment Percent Change in High-Density Lipoprotein (HDL) Levels

The reported percent change is the difference between HDL levels obtained on initial visit (day 0) and HDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)

Intervention% change (Mean)
Rosiglitazone and Placebo1.9
Fenofibrate + Placebo14.5
Rosiglitazone +Fenofibrate5.8
Placebo Therapy Daily1.7

Post-treatment Percent Change in Low-Density Lipoprotein (LDL) Levels

The reported percent change is the difference between LDL levels obtained on initial visit (day 0) and LDL levels obtained at final visit (week 12) as per protocol (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)

Intervention% change (Mean)
Rosiglitazone + Placebo-0.5
Fenofibrate + Placebo2.6
Rosiglitazone + Fenofibrate37.3
Placebo Therapy Daily13.7

Mean Levels of Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) at Initial Visit and Final Visit

The mean Levels of AST and ALT measured at initial visit (Day 0) and final visit (Week 12) annotated as AST 1, AST 12, and ALT 1 and ALT 12, respectively. (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)

,,,
Interventionmg/dl (Mean)
AST 1 (aspartate aminotransferase [10-35 U/L])AST 12 (aspartate aminotransferase [15-37 U/L])ALT 1 (alanine aminotransferase [6-60 U/L])ALT 12 (alanine aminotransferase [6-60 U/L])
Fenofibrate + Placebo25.2526.5025.8826.38
Placebo Therapy Daily19.8817.8820.8814.88
Rosiglitazone + Placebo24.0030.2928.1427.43
Rosiglitazone +Fenofibrate24.3019.7024.1021.10

Post-treatment Percent Change in Apolipoprotein A-I (Apo AI), Apolipoprotein A-II (Apo AII) and Apolipoprotein C-III (Apo CIII) Levels

Post-treatment median change in Apo AI, Apo AII and Apo CIII levels reported in mg/dL with Interquartile ranges provided (NCT00819910)
Timeframe: 12 weeks from initial visit (day 0) to final visit (12 weeks)

,,,
Intervention% Change (Median)
Apo AIApo AIIApo CIII
Fenofibrate + Placebo133.4-4.35
Placebo Therapy Daily5-3.5-2.3
Rosiglitazone + Placebo-1.0010.250.30
Rosiglitazone +Fenofibrate17.2-5.3

Reviews

5 reviews available for troglitazone and Diabetic Angiopathies

ArticleYear
Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions.
    Current cardiology reports, 2002, Volume: 4, Issue:6

    Topics: Adipose Tissue; Animals; Chromans; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies

2002
Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes.
    Cardiology clinics, 2005, Volume: 23, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Animals; Biguanides; Blood Pressure; Chromans; Diabetic Angiopathies

2005
[Treatment of hypertension associated with diabetes mellitus].
    Nihon rinsho. Japanese journal of clinical medicine, 1997, Volume: 55, Issue:8

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chroma

1997
Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
    Drugs, 1999, Volume: 58 Suppl 1

    Topics: Animals; Blood Glucose; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetic Angio

1999
Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.
    Diabetes technology & therapeutics, 2000,Summer, Volume: 2, Issue:2

    Topics: Acarbose; Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Human

2000

Trials

6 trials available for troglitazone and Diabetic Angiopathies

ArticleYear
The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.
    Metabolism: clinical and experimental, 2003, Volume: 52, Issue:2

    Topics: Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Fasting; Female;

2003
The Diabetes Prevention Program.
    Current diabetes reports, 2003, Volume: 3, Issue:3

    Topics: Adult; Cardiovascular Diseases; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Ang

2003
Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes.
    Obesity research, 2005, Volume: 13, Issue:7

    Topics: Adiponectin; Adult; Aged; Brachial Artery; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathie

2005
Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study.
    Journal of the American College of Cardiology, 2000, Nov-01, Volume: 36, Issue:5

    Topics: Cell Division; Chromans; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female;

2000
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Diabetes care, 2002, Volume: 25, Issue:3

    Topics: Blood Glucose; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Chromans; D

2002
Cardiac hypertrophy in diabetes patients with and without hypertension: effects of troglitazone, a novel antidiabetic drug, on diastolic function.
    Advances in experimental medicine and biology, 2001, Volume: 498

    Topics: Cardiomegaly; Chromans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diastole; Female; Humans;

2001

Other Studies

2 other studies available for troglitazone and Diabetic Angiopathies

ArticleYear
PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase.
    Circulation research, 2004, Jun-11, Volume: 94, Issue:11

    Topics: Animals; Aorta; Cattle; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Chromans; Diabetic

2004
Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus.
    The American journal of cardiology, 1999, Jul-01, Volume: 84, Issue:1

    Topics: Angina Pectoris, Variant; Chromans; Diabetic Angiopathies; Endothelium, Vascular; Humans; Insulin Re

1999